This study is in progress, not accepting new patients
Siplizumab in T1DM
Summary
- Eligibility
- for people ages 8-45 (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Stephen Gitelman, M.D. (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Stephen Gitelman, M.D. (ucsf)
Dr. Gitelman is a physician scientist involved in studies to determine what causes type 1 diabetes mellitus (T1DM), and in clinical trials to prevent disease development, or preserve beta cell function in those recently diagnosed. To this end, he has been an active investigator in the NIH-sponsored TrialNet and Immune Tolerance Network consortia, and other immunotherapy trials in T1DM.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Links
- Immune Tolerance Network (ITN)
- ID
- NCT05574335
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 120 study participants
- Last Updated